Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | BCHE | P06276 | 1/20 | 0.45 |
| ▸ | TRPC3 | Q13507 | 1/20 | 0.45 |
| ▸ | TRPC4 | Q9UBN4 | 1/20 | 0.45 |
| ▸ | TRPC5 | Q9UL62 | 1/20 | 0.45 |
| ▸ | SLC9A1 | P19634 | 4/20 | 0.45 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5858860 | 0.89 | TAAR1 (0.47) | ALDH1A1EGLN3IDO1POLBTAAR1 | |
| Pyrrolidine SCHEMBL5862139 | 0.85 | ALDH1A1 (0.39) | ALDH1A1BCHETRPC3TRPC4TRPC5 | |
| SCHEMBL5858759 | 0.84 | FPR1 (0.49) | ALDH1A1 | |
| SCHEMBL5858816 | 0.84 | ACHE (0.43) | ALDH1A1BCHEEGLN3IDO1POLB | |
| Hydrochloric Acid SCHEMBL5859902 | 0.83 | ACHE (0.42) | ALDH1A1BCHEEGLN3IDO1POLB | |
| SCHEMBL5858811 | 0.82 | EGLN3 (0.40) | ALDH1A1EGLN3IDO1POLBTAAR1 | |
| SCHEMBL5858785 | 0.82 | ALOX12 (0.46) | ALDH1A1EGLN3IDO1POLBTAAR1 | |
| SCHEMBL5858821 | 0.80 | TAAR1 (0.41) | ALDH1A1EGLN3IDO1POLBTAAR1 | |
| SCHEMBL5861859 | 0.78 | IDO1 (0.43) | ALDH1A1EGLN3IDO1POLBTAAR1 | |
| SCHEMBL27682492 | 0.77 | ALDH1A1 (0.61) | ALDH1A1BCHETRPC3TRPC4TRPC5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7030140-B2 | Substituted benzimidazole antiviral agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-04-18 | — | — | US | disclosed |
| US-6908936-B2 | Substituted benzimidazole antiviral agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-06-21 | — | — | US | disclosed |
| US-20050038085-A1 | Substituted benzimidazole antiviral agents | YU KUO-LONG (US) | 2005-02-17 | — | — | US | disclosed |
| US-20030139450-A1 | Substituted benzimidazole antiviral agents | YU KUO-LONG (US) | 2003-07-24 | — | — | US | disclosed |
| EP-1098644-A1 | SUBSTITUTED BENZIMIDAZOLE ANTIVIRAL AGENTS | Bristol-Myers Squibb Company (US) | 2001-05-16 | — | — | EP | disclosed |
| WO-2000004900-A1 | SUBSTITUTED BENZIMIDAZOLE ANTIVIRAL AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038085-A1 | Substituted benzimidazole antiviral agents | MAVS, ZC3HAV1, ZC3HAV1L | ALDH1A1 1674/4885BCHE 2155/4885TRPC3 3870/4885 |
| US-20030139450-A1 | Substituted benzimidazole antiviral agents | MAVS, ZC3HAV1, ZC3HAV1L | ALDH1A1 1674/4885BCHE 2155/4885TRPC3 3870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.